China NMPA Clears CSPC's SYH-2083 for Clinical Trials in Dry Eye Disease
核心洞察
CSPC (搜索) has received clearance in China to begin clinical testing of SYH-2083 (搜索) for the treatment of dry eye disease (搜索).
The clearance was reported in BioWorld Asia briefs dated Sept. 8, 2026, alongside other early-stage and regulatory developments.
The same briefs noted an FDA advisory committee vote against Astrazeneca's Etcamah (camizestrant) in first-line breast cancer (搜索) about four months earlier.
CSPC (搜索) has received clearance in China to begin clinical development of SYH-2083 (搜索) for dry eye disease (搜索), according to BioWorld Asia briefs dated Sept. 8, 2026.
The item appeared alongside other pipeline and regulatory news in the same briefs. Among those items, an FDA advisory committee voted against Astrazeneca plc's Etcamah (camizestrant) for first-line breast cancer (搜索) a little more than four months before the briefs were published.
Other entries covered dual serotonin receptor targeting to boost cognition and curb psychosis, presented at the European Federation for Medicinal Chemistry and Chemical Biology's International Symposium on Medicinal Chemistry, and single-cell RNA sequencing work from Technion and collaborating institutions identifying subtypes of the tumor microenvironment linked to checkpoint blockade success.